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Abstract
Background: The term premature pubarche (PP) refers to 
the appearance of pubic hair before age 8 in girls and before 
age 9 in boys. Although idiopathic PP (often associated with 
premature adrenarche) is considered an extreme variation 
from the norm, it may be an initial sign of persistent hyper-
androgenism. Factors contributing to PP onset and progres-
sion have not been identified to date. Aims: The objectives 
of this study are to describe a group of Italian children with 
PP, to identify potential factors for its onset, and to define its 
clinical and biochemical progression. Methods: We retro-
spectively enrolled all infants born between 2001 and 2014 
with PP. Children with advanced bone age (BA) underwent 
functional tests to determine the cause of PP. Hormonal 
analysis and BA determination were performed annually 
during a 4-year follow-up period. Results: A total of 334 chil-
dren with PP were identified: idiopathic PP (92.5%, associ-
ated with premature adrenarche in some cases); related to 
precocious puberty (6.6%); late-onset 21-hydroxylase defi-
ciency (0.9%). Low birth weight was associated with prema-
ture adrenal activation. Body mass index (BMI) was the only 
factor that influenced the progression of BA during follow-
up. Conclusions: Low birth weight is a predisposing factor 
for premature adrenal activation. The increase in BMI in pa-
tients with idiopathic PP during the 4-years of follow-up was 
responsible for BA acceleration. We recommend prevention 
of excessive weight gain in children with PP and strict adher-
ence to follow-up in order to prevent serious metabolic con-
sequences. © 2020 S. Karger AG, Basel
Introduction
Premature pubarche (PP) refers to the appearance of 
pubic hair, often accompanied by axillary hair, before the 
age of 8 in girls and before the age of 9 in boys [1]. It oc-
curs more frequently in females, and the cause of the un-
equal sex ratio is unknown [2–4]. In the majority of cases, 
PP is idiopathic (due to premature adrenarche) and can 


























































Other disorders, such as milder and nonclassical congen-
ital adrenal hyperplasia (CAH), Cushing’s disease, viril-
izing tumors originating from the adrenals or the gonads, 
or more rare conditions, may also manifest with PP [3, 6, 
7]. A diagnosis of precocious puberty should be consid-
ered in patients with progressive signs of pubertal devel-
opment (e.g., breast development in girls and penile or 
testicular growth in boys) besides clinical signs of PP [3].
The pathophysiological basis of idiopathic PP and pre-
mature adrenarche is unknown [1]. It is secondary to ear-
ly and isolated maturation of the zona reticularis of the 
adrenal cortex and is triggered by the activation of andro-
gen production, resulting in a dramatic increase in serum 
DHEAS levels [8–10]. DHEAS levels ≥40–50 μg/dL are 
consistent with the onset of adrenarche [3, 11, 12]. 
DHEAS is converted to active androgens in the gonads 
and the peripheral target tissues of androgen action, in-
cluding the skin, leading to the appearance of pubic and 
axillary hair. Increased androgen production also brings 
about changes in body odor and oily skin, transient 
growth spurt, and it contributes to bone maturation [7, 
13, 14]. In patients with PP, however, bone age (BA) ad-
vancement is linked not only to elevated DHEAS levels 
but also to obesity, another concurrent factor in these 
children [12, 13]. Finally, hypersensitivity of hair follicles 
to steroid hormones has been hypothesized in children 
with PP and normal androgen levels [5, 15].
Idiopathic PP is considered an extreme variation from 
the norm; as such, it is a serious source of concern for 
parents. Furthermore, it may be a risk factor for later dys-
function of the reproductive endocrine system [3, 7, 12]. 
The main question is whether idiopathic PP (and prema-
ture adrenarche) is a form of early adrenal maturation or 
an initial sign of persistent hyperandrogenism. To answer 
this question, studies have investigated the potential fac-
tors for PP onset; however, none to date has been conclu-
sively identified as a regulator of adrenal androgen secre-
tion. Ethnic origin, elevated body mass index (BMI), and 
weight gain have all been reported to be factors contribut-
ing to adrenarche [3, 8, 12], whereas elevated 17-hydroxy-
progesterone (17-OHP) level at newborn screening has 
been recently excluded as a predictive factor for PP [16]. 
Furthermore, we do not know which predictor factors are 
able to identify the clinical and biochemical progression 
of PP during infancy and puberty. With the abovemen-
tioned points in mind, the aims of this study were to de-
scribe a group of Italian children with PP, to identify po-




For this retrospective study, we reviewed the clinical data of 
Caucasian patients born between 2001 and 2014 referred to the 
Pediatric Endocrinology Division of Verona Hospital, Italy, for the 
appearance of pubic hair before the age of 8 in girls and before the 
age of 9 in boys. Weight, height, and BMI (weight in kg/height in 
m2) were recorded. The height, weight, and BMI standard devia-
tion score (SDS) were derived from Italian cross-sectional growth 
charts [17]. Pubertal development was evaluated according to 
Tanner and Whitehouse [18]. For boys, testicular volume was 
measured using a Prader orchidometer.
Gestational age (GA), birth weight (BW), and birth length (BL) 
were evaluated, and familiar genetic target was calculated accord-
ing to the parents’ height. Target height was determined by calcu-
lating the midparental height as follows: ([father’s height cm − 13 
cm] + mother’s height cm)/2 for girls; ([mother’s height cm + 13 
cm] + father’s height cm)/2 for boys [19]. Children born small for 
gestational age (SGA) were defined according to Bertino Neonatal 
Anthropometric Charts [20]. We defined SGA as a newborn with 
a birth weight and/or length of <−2 SD according to the Consensus 
Statement of the International Societies of Pediatric Endocrinol-
ogy and of the Growth Hormone Research Society [21]. Figure 1 
presents the study flowchart showing the number of patients and 
type of tests and radiological exams performed.
Radiography was performed in all children to determine BA, 
which was evaluated by the same pediatric endocrinologist using 
the Greulich and Pyle method [22]. Children with advanced BA 
(ratio of BA to chronological age >1) underwent the adrenocorti-
cotropic hormone (ACTH) stimulation test (intravenous admin-
istration of soluble Synacthen 250 mg). Serum 17-OHP and corti-
sol levels were measured at baseline and after 60 min. Data were 
analyzed using Maria New nomogram [23]. Levels of testosterone, 
ACTH, DHEAS, and Δ4-androstenedione were also measured.
Children with clinical signs of precocious puberty (Tanner 
stage ≥ B2 in girls and testicular volume ≥4 mL in boys) were sub-
mitted to GnRH-analogue (GnRH-a) stimulation testing (subcu-
taneous administration of 0.1 mg of GnRH-a (Triptorelin) after 
overnight fasting). Serum levels of follicle-stimulating hormone 
(FSH), luteinizing hormone (LH), estradiol in females, and testos-
terone in males were measured at baseline and 4 h afterward. A LH 
peak of ≥15 U/L was indicative of activation of the hypothalamic-
pituitary-gonadal (HPG) axis in both sexes.
Abdominal, pelvic, and/or testicular ultrasound studies were 
performed in patients with elevated androgen levels and advanced 
BA to exclude organic causes for PP, such as ovarian, testicular, or 
adrenal tumors. Pelvic ultrasound was performed to measure uter-
ine and ovarian size in females with pubertal signs.
Children with idiopathic PP and advanced BA, born between 
2001 and 2012, were followed up for an average period of 4 years. 
Children born after 2012 were excluded from the present analysis 
because the follow-up period was not yet complete. Exams at fol-
low-up assessment included repeated BA and hormonal analysis 
(DHEAS, Δ4-androstenedione, ACTH, and cortisol). Two groups 
were formed based on DHEAS level at the time of diagnosis.
The present study was conducted in compliance with the terms 
of the Helsinki II Declaration. The Institutional Ethics Committee 
of the provinces of Verona and Rovigo, Italy, took note of the ret-


























































the results. Written, informed consent was obtained from the 
child’s parents or legal guardian.
Assay
Serum total testosterone, ACTH, cortisol, Δ4-androstenedione, 
DHEAS, estradiol, FSH, and LH were measured using a solid-
phase, competitive chemiluminescent enzyme immunoassay (Im-
mulite 2000; Siemens Healthcare Diagnostic, USA). The analytical 
sensitivity was 14.4 ng/dL for total testosterone, 5 pg/mL for 
ACTH, 0.2 μg/dL for cortisol, 0.3 ng/mL for Δ4-androstenedione, 
0.3 μg/dL for DHEAS, 0.1 U/L for FSH, 0.05 U/L for LH, and 15 
pg/mL for estradiol.
Intraassay and interassay coefficients of variation were 11.7 and 
13.0%, respectively, for testosterone; 9.5 and 10.0%, respectively, 
for ACTH; 7.4 and 9.4%, respectively, for cortisol; 9.3 and 12%, 
respectively, for Δ4-androstenedione; 4.1 and 6.3%, respectively, 
for DHEAS; 2.9 and 4.1%, respectively, for FSH; 3.6 and 6.7%, re-
spectively, for LH; 11.7 and 13%, respectively, for estradiol. Serum 
17-OHP was assayed using a radioimmunoassay (DSL-5000 Ac-
tive 17α-OH Progesterone Coated-Tube Radioimmunoassay, Dia-
sorin, Saluggia, Italy). The assay sensitivity was 0.01 ng/dL, and 
intra- and interassay coefficients of variation were both 9.0%.
Statistical Analysis
Statistical analyses were performed using software R version 
3.5.1 (R Core Team [2018] R: A language and environment for sta-
tistical computing; R Foundation for Statistical Computing, Vi-
enna, Austria). Since the majority of the variables were not nor-
mally distributed, nonparametric statistics were employed. The 
Mann-Whitney U test was used to compare differences between 2 
independent groups, and Friedman’s nonparametric ANOVA was 
employed to compare differences between time points. Multiple 
linear regression analysis was also performed in order to explore 
the relationship between DHEAS levels and selected independent 
variables (BW SDS, GA, BMI SDS, age, and sex) at the time of 
DHEAS measurement. Furthermore, multiple regression analysis 
was performed at the last follow-up visit using BA acceleration 
(ΔBA) as the dependent variable and BMI SDS, sex, age, GA, Tan-
ner genital/breast stage, and serum DHEAS as independent vari-
ables.
Correlations were evaluated using either the Spearman or the 
Pearson correlation test, when appropriate. Fisher’s exact test was 
used to compare 2 proportions. Data are expressed as numbers 
with frequency, median plus range, or mean ± SD, as appropriate. 
Statistical significance was set at p ≤ 0.05.
Results
Between 2001 and 2014, we identified 334 patients 
with PP (271 females and 63 males). Table 1 presents the 
clinical data and the neonatal characteristics of the pa-
tients. Forty children (12%) in the cohort were born pre-
mature and 8 (2.4%) were SGA; 43.7% of the children 
were overweight.
Of the total of 334 patients, 112 (97 females and 15 
males) had a BA to chronological age ratio of >1 (Fig. 1). 
The difference between BA and chronological age was 1.3 
± 1.0 years for the females and 1.4 ± 1.0 years for the 
334 patients with PP
(F 271, M 63)
Advanced BA: 112 patients
(F 97, M 15)
GnRH-a test
Weight, height, BMI,
pubertal development, bone age (BA)
BA ≤ chronological age:
222 patients (F 174, M 48)
Precocious puberty:
22 patients (F 21, M 1) 
Late onset CAH: 3
patients (F 2, M 1)
Non CAH: 109 patients
(F 95, M 14)
Signs of puberty (B2, G2):
60 patients (F 55, M 5)
Idiopathic PP: 55
patients (F 48, M 7)
Slightly increased androgen





patients (F 41, M 7)
Idiopathic PP: 206
patients (F 159, M 47)



























































males. The mean age was 7.3 ± 1.8 years for the females 
and 8.6 ± 1.3 years for the males. Table 2 presents the re-
sults of blood analysis to identify the etiology of PP and 
the results of the GnRH-a test to determine activation of 
the HPG axis in the 60 children presenting clinical signs 
of puberty.
PP was defined as idiopathic in 92.5% (248 females and 
61 males), related to precocious puberty in 6.6% (21 fe-
males and 1 male) and a manifestation of late-onset CAH 
due to 21-hydroxylase deficiency (21-OHD) in 0.9% (2 
females and 1 male). In 25 children (24 females and 1 
male), the 17-OHP level measured at the ACTH test was 
compatible with being heterozygous for 21-OHD based 
on Maria New nomogram [22].
Comparison between the females with precocious pu-
berty and those with idiopathic PP and advanced BA 
showed that those with precocious puberty were older 
(8.0 ± 0.9 vs. 7.2 ± 1. 2 years, p = 0.043) and had higher 
FSH and LH basal levels (FSH 4.2 ± 2.5 vs. 1.8 ± 1.6 U/L; 
LH 1.3 ± 1.5 vs. 0.2 ± 0.9 U/L; p < 0.001 for all compari-
sons). Basal LH >2.2 U/L and basal FSH >8.7 U/L levels 
were predictive of precocious puberty (sensitivity 99.3%). 
Owing to the small number of males, these data were an-
alyzed only for the females.
Clinical and biochemical evaluation was performed 
annually for 4 years in all patients with idiopathic PP and 
advanced BA (87 females and 13 males). Ten children in 
the cohort (10%) were born preterm, and one (1%) was 
SGA. Three children (2 females and 1 male) were exclud-
ed from this analysis because they were born after 2012. 
At each assessment, hormonal levels, auxological data, 
and BA were recorded with a particular focus on 2 param-
eters: growth rate and ΔBA (difference between bone and 
chronological age). A growth rate of >5.5 cm/year and an 
Table 1. Clinical characteristics of all patients at diagnosis and at birth
Females (n = 271) Males (n = 63)
Age, years 7.2±1.7 (0.5 to 10.3) 7.8±2.1 (0.4 to 9.9)
Weight SDS 3.1±2.1 (−1.3 to 11.4) 3.0±2.4 (−1.6 to 7.9)
Height SDS 2.0±1.2 (−1.7 to 5.4) 1.8±1.2 (−1.3 to 5.3)
BMI SDS 2.0±1.2 (−2.2 to 9.9) 2.5±2.7 (−2.2 to 8.6)
Target height SDS 0.2±0.9 (−2.4 to 2.9) 0.4±0.9 (−1.5 to 2.4)
Pubic hair, n (%)
Tanner Ph 2 247 (91.1) 57 (90.5)
Tanner Ph 3 24 (8.9) 6 (9.5)
Tanner Ph 4 0 0
Tanner Ph 5 0 0
Axillary hair, n (%)
Tanner A1 249 (91.9) 60 (95.2)
Tanner A2 20 (7.4) 2 (3.2)
Tanner A3 2 (0.7) 1 (1.6)
Breast, n (%)
Tanner B1 216 (79.7) –
Tanner B2 43 (15.9)




Tanner G1 – 58 (92)




GA, weeks 38.6±2.5 (25.0 to 42.1) 38.1±2.7 (29.0 to 41.0)
BW, g 3,045.9±638.0 (787.0 to 5,000.0) 3,081.0±746.9 (950.0 to 4,260.0)
BL, cm 49.3±2.8 (25.0 to 54.5) 49.9±3.5 (35.0 to 55.0)
Data are expressed as mean ± SD and range in the brackets. SDS, standard deviation score; GA, gestational 


























































advanced BA of >1.5 years were considered a marker of 
progression of the condition. No predictive factor for 
growth rate was identified; the only factor that was posi-
tively and significantly (p = 0.011) associated with Δ BA 
was BMI (Fig. 2). This association remained significant 
(p = 0.007) even after having adjusted for the effects of 
sex, age, GA, Tanner genital/breast stage, and serum 
DHEAS.
The cohort was divided into 2 groups according to se-
rum DHEAS level: one group with PP and elevated 
DHEAS (≥40 μg/dL) and the other with PP and normal 
DHEAS (<40 μg/dL). Table 3 presents the characteristics 
of the 2 groups. The group with elevated DHEAS was not-
ed to have had a lower weight at birth (p < 0.05), suggest-
ing an association between lower BW and higher adrenal 
androgen secretion (Fig.  3). Multiple linear regression 
analysis confirmed this observation; serum levels of 
Table 2. Blood exams (ACTH test and GnRH-analogue test) at the time of diagnosis
Females (n = 112) Males (n = 16)
Δ4-androstenedione, ng/mL 0.6±0.5 (0.3–3.0) 0.7±0.4 (0.3–1.9)
DHEAS, μg/dL 66.6±42.5 (0.4–248.0) 117.8±58.3 (15.0–291.0)
ACTH, pg/mL 29.1±44.8 (6.2–373.0) 27.2±26.3 (8.7–135.0)
ACTH test
Cortisol basal, µg/dL 11.8±8.6 (1.6–6.0) 9.5±4.5 (6.1–29.6)
Cortisol peak, µg/dL 26.8±5.4 (1.0–42.9) 24.4±5.8 (4.7–33.3)
17 OHP basal, ng/dL 1.2±2 (0.1–15.7) 1.7±3.7 (0.3–18.0)
17 OHP peak, ng/dL 4.7±8.9 (1.1–76.0) 7.5±20.7 (1.5–110.0)
GnRH-analogue test
FSH basal, U/L 2.2±1.9 (0.1–9.7) 1.2±1.1 (0.3–4.3)
FSH peak, U/L 22.9±13.1 (1.7–83.6) 9.5±4.6 (3.7–19.4)
LH basal, U/L 0.4±1.1 (0.1–10.0) 0.3±0.4 (0.1–1.8)
LH peak, U/L 8.1±16.3 (0.1–111.0) 6.5±6.8 (0.9–27.3)
Estradiol basal, pg/mL 38.2±28.1 (80.2–195.0) –
Estradiol peak, pg/mL 40.1±35.2 (19.8–264.0) –
Testosterone basal, ng/dL – 20.3±6.8 (0.3–39.6)
Testosterone peak, ng/dL – 22.3±14.7 (2.1–72.8)
Data are expressed as mean ± SD and range in the brackets. ACTH, adrenocorticotropic hormone; FSH, 














Fig. 2. Relationship between BMI SDS and 
the difference between bone age and chron-
ological age (ΔBA) (R = 0.26; p = 0.011). 
The bone age used for the ΔBA was deter-
mined during the last follow-up visit, and 
the BMI shown in the figure was deter-
mined at the same visit. BMI, body mass 


























































DHEAS (dependent variable) were significantly (p < 
0.001) associated with BW SDS even after having adjusted 
for the effects of sex, age, GA, and BMI SDS. In group with 
DHEAS ≥40 μg/dL, 16% had a BW of <2,500 g, whereas 
in the other group (DHEAS <40 μg/dL), only 2.6% had a 
BW of <2500 g (p < 0.05). The serum Δ4-androstenedione 
levels were higher in the group with elevated DHEAS, 
with a positive correlation between the serum DHEAS 
and Δ4-androstenedione levels measured during the fol-
low-up (p < 0.05). The serum ACTH and cortisol levels 
remained stable during the follow-up period. We found a 
significant difference between DHEAS levels in the 2 
groups at each assessment during the 4 years of follow-up 
(p < 0.05) (Fig. 4). The growth rate in both groups was 
regular without a significance difference during the fol-
low-up; there was a slight increase in the percentage of 
overweight children (from 50.5% at year 1 to 51.8% at 
year 4), without significance differences between the 2 
groups. Pubertal development began at age 8.9 ± 0.7 years 
in the females and at age 10.8 ± 1.2 years in the males. 
These data did not differ between the children born pre-
term and those born at term.
Discussion
For this retrospective study, we analyzed a cohort of 
patients of Caucasian origin with PP followed up for a 
minimum of 4 years at a single center in northeast Italy. 
Idiopathic PP was diagnosed in the majority of patients, 
and body weight played a role in the onset and the clinical 







–3 –2 –1 0 1 2 3
R = –0.21
Birth weight (SDS) 
DHEAS, 
µg/dL
Table 3. Main characteristics of the 2 groups based on DHEAS levels at the time of diagnosis
DHEAS <40 μg/dL (n = 38) DHEAS ≥40 μg/dL (n = 62) p value
GA, weeks 38.8±2.6 (26.0–41.0) 38.3±2.6 (25.0–41.0) 0.261
BW, g 3,248.6±564.2 (1,000.0–5,000.0) 2,956.5±666.4 (787.0–4,660.0) 0.003
BL, cm 49.9±2.9 (51.0–54.0) 49.4±2.4 (41.0–55.0) 0.368
BMI, kg/m2 18.8±2.5 (14.8–26.2) 16.9±6.6 (13.3–28.3) 0.810
Δ4-androstenedione, ng/mL 0.4±0.2 (0.3–1.1) 0.6±0.4 (0.3–3.0) 0.007
ACTH, pg/mL 32.7±53.7 (9.0–373.0) 27.6±38.3 (6.2–344.0) 0.494
Testosterone, ng/dL 6.5±9.4 (0.2–20.0) 7.1±10.9 (0.2–20.0) 0.748
Cortisol, µg/dL 11.3±5.5 (3.6–26.3) 10.5±6.0 (1.6–36.4) 0.420
Data are expressed as mean ± SD and range in the brackets. Bold values represent statistical significance. GA, 
gestational age; BW, birth weight; BL, birth length; ACTH, adrenocorticotropic hormone.
Fig. 3. Inverse relationship between 
DHEAS level at the time of diagnosis and 
birth weight (BW SDS): patients with lower 
BW had higher serum DHEAS levels (R = 



























































ture adrenal activation and increased BMI was the only 
factor that influenced BA acceleration during the follow-
up period.
Only 3 patients in the cohort presented late-onset 
CAH, consistent with a prevalence estimated between 0 
and 40% [7, 24–27]. Furthermore, 7.5% presented 17-
OHP levels at the ACTH test indicative of heterozygosity 
for 21-OHD. Although genetic analysis was not per-
formed, we hypothesized an association between hetero-
zygosity for 21-OHD and the presence of PP. This asso-
ciation has been variously studied [16, 28–30] with some 
studies reporting a similar risk for mutation carriers and 
normal subjects [31, 32] and others underlining the as-
sociation, especially in subjects carrying the V281L muta-
tion [33, 34]. The mechanism behind this association re-
mains unknown.
Precocious puberty was noted in 6.6% of the patients 
with PP. PP may be secondary to or concomitant with 
precocious puberty. The incidence of precocious puberty 
was higher in the females, as reported elsewhere [35]. 
There was a significant difference between basal LH and 
FSH levels in the girls with precocious puberty compared 
to those with idiopathic PP. LH >2.2 U/L was associated 
with activation of the HPG axis (sensitivity 99%). The role 
of basal LH in the diagnosis of precocious puberty has 
been discussed in the literature; however, the consensus 
statement on precocious puberty recommends luteiniz-
ing hormone-releasing hormone or GnRH-a testing to 
identify central precocious puberty [36]. While we doubt 
that baseline LH is sufficient for a diagnosis of precocious 
puberty, LH levels >2.2 U/L in girls with PP and thelarche 
should arouse suspicion. Previous studies showed in fact 
that elevated basal LH levels were significant predictors 
of central precocious puberty and suggested a threshold 
of LH >1.6 U/L [37–39].
Although PP is a relatively common, usually nonpro-
gressive, clinical sign, its natural history is not well known 
[8]; it may be correlated with metabolic disorders includ-
ing obesity, hyperinsulinism, hyperandrogenism, and 
polycystic ovary syndrome in females [1, 3, 7]. No factors 
contributing to PP onset and progression have been iden-
tified to date. Numerous studies found a relationship be-
tween low BW and androgen excess [3, 8, 12, 40]. Weight 
gain during infancy seems to trigger adrenarche [1]. Some 
studies have hypothesized that malnutrition in prenatal 
life could lead to metabolic programming of fetal organs 
and result in metabolic alterations, such as hyperinsu-
linemia and premature androgen excess [8, 41]. While 
French, Portuguese, Finnish, and Scottish studies report-
ed no association with low BW in children with prema-
ture adrenarche [42–45], other studies from Spain, Italy, 
France, and Australia found a correlation between low 
BW and adrenarche [46–49], which our data confirm. A 
role for low BW in the onset of adrenarche in relation to 
country of origin has not been established, but genetic 
diversity might be responsible for the difference [9]. The 
relationship that we found between premature adre-
narche and BW was adjusted for sex, age, GA, and BMI. 
Consequently, it is possible to exclude a role of preterm 
delivery in the onset of premature adrenarche. Although 
SGA patients may also experience premature adrenarche 
[12, 49], only 1 patient in the cohort was born SGA, pre-
cluding definitive conclusions about its role.
PP has been associated with obesity, hyperinsulinemia, 
and hyperandrogenism; however, it is not clear whether 
the primum movens is overweight or hyperandrogenism. 
A higher prevalence of overweight among children with 
















































Fig. 4. Mean serum DHEAS (panel a) and 4-androstenedione 
(panel b) levels during 3 years of follow-up in the 2 groups (DHEAS 
>40 or <40 μg/dL at the time of diagnosis). We found a significant 
difference between DHEAS levels during the follow-up in the 2 
groups at each evaluation (p < 0.05). There was a significant differ-
ence in ∆4-androstenedione levels between the 2 groups only at the 


























































weight is thought to be involved in the onset of pubarche 
[1, 3]. Some studies have shown that overweight girls tend 
to experience an earlier onset and a more rapid evolution 
of puberty and pubarche [53–55]. Other studies have de-
scribed PP as an early clinical feature of metabolic syn-
drome [50, 56]. Our data suggest that hyperandrogenism 
is a primary factor and overweight a secondary factor. 
Although overweight was predominant in this cohort, 
both at diagnosis and during follow-up, we found no as-
sociation between PP and overweight. On the contrary, 
during the follow-up, when adrenal androgen secretion 
was already active, the rise in BMI played an important 
role in the advancement of BA. Obese children are noted 
to present advanced BA secondary to increased adipose 
tissue aromatization of androgens into estrogens, which 
are the sex hormones critically involved in skeletal matu-
ration [12, 50]. In addition, hyperinsulinemia and high 
leptin levels, both consequences of obesity, can contrib-
ute to bone maturation. Hyperinsulinemia can act on the 
IGF-1 receptor and stimulate growth, while leptin ap-
pears to act as a skeletal growth factor [57, 58]. Further-
more, androgen action, which potentiates the effect of 
obesity on advancement of BA, has been described in 
children with obesity and/or pubarche [13, 59, 60] but not 
confirmed by the data for our cohort.
The role of androgens in PP is debated. DHEA and 
DHEAS are the best serum markers of adrenal androgen 
secretion [3]. The variable peripheral conversion of these 
circulating adrenal androgen precursors to the biologi-
cally more active androgens, testosterone and dihydrotes-
tosterone, is essential for androgen action. Normal ACTH 
secretion and action are needed for adrenarche [3, 8, 12]. 
The data for our cohort show normal testosterone, ACTH, 
and cortisol concentrations. Moreover, we observed a lin-
ear rise in DHEAS and Δ4-androstenedione levels, which 
gradually increased over the 4-year follow-up period. We 
believe that in addition to DHEAS, the elevated Δ4-
adrostenedione levels were also a marker of adrenarche 
in our cohort; however, this hypothesis needs to be con-
firmed in larger patient populations in prospective clini-
cal trials. Furthermore, since Δ4-adrostenedione can be 
formed peripherally from DHEAS, as well as directly 
from the gonads, circulating Δ4-adrostenedione levels do 
not necessarily reflect the adrenal production rate [3]. Fi-
nally, we found no direct relationship between androgen 
concentrations and obesity, advancement of BA, and in-
creased growth rate.
During the 4-year follow-up, the children in the cohort 
presented a regular and linear growth rate, confirming 
previous data which described only a transient accelera-
tion in growth in children with PP. Moreover, pubertal 
development began at normal age in both sexes, in line 
with previous studies [3, 12, 14, 61, 62].
The limitations of this study are its retrospective de-
sign, the lack of a control group, the absence of meta-
bolic data, the absence of final height and weight, and a 
population sample consisting only of patients of Cau-
casian origin. Nevertheless, the objective was to de-
scribe a cohort of Italian children with PP and to iden-
tify potential predictive factors for its onset and pro-
gression. Evaluation of metabolic disorders or final 
height and weight was beyond the scope of the present 
study but will be an area of focus in a future study. Eth-
nicity seems to play a role in the onset of PP, with a 
higher prevalence reported among Hispanic and Afri-
can-American girls [1, 8]. Data for other ethnic groups 
would have been interesting to evaluate, but given the 
lack of ethnic diversity in our area, we could not have 
drawn any meaningful conclusions.
In conclusion, the mechanism underlying PP remains 
unclear and is probably of multifactorial etiology. Low 
BW is a predisposing factor for premature adrenarche 
among children born in northeast Italy; the clinical and 
biochemical progression of PP depends on diverse fac-
tors, including increased BMI, which is responsible for 
BA acceleration. We recommend prevention of excessive 
weight gain in children with PP and strict adherence to 
follow-up in order to prevent serious metabolic conse-
quences.
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